Evidence map›Paper›PMID 31720707›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2020

Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures.

J A Kanis, N C Harvey, E McCloskey, O Bruyère, N Veronese, M Lorentzon, C Cooper, R Rizzoli, G Adib, N Al-Daghri and 16 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 194 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
194citing papers in PubMed, 15 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

194 citing papers in PubMed, 15 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Guideline
  4. PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
    Pooled it
  5. Romosozumab for the treatment of osteoporosis - a systematic review.Journal of endocrinological investigation · 2025
    Pooled it
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Guideline
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. A systematic review of cost‑effectiveness analyses of sequential treatment for osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2023
    Pooled it
  15. Guideline
  16. Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2024
    Trial
  17. Trial
  18. Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability-results from the Women's Health Initiative hormone therapy trials.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022
    Trial
  19. Trial
  20. Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021
    Trial

134 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

J A KanisCentre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, S10 2RX, Sheffield, UK. w.j.Pontefract@shef.ac.uk.ORCID http://orcid.org/0000-0002-3129-4326
N C HarveyMRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.
E McCloskeyCentre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, S10 2RX, Sheffield, UK.
O BruyèreWorld Health Organization Collaborating Center for the Public Health Aspects of Musculoskeletal Health and Aging, Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.
N VeroneseNational Research Council, Neuroscience Institute, Aging Branch, Via Giustiniani, 2, 35128, Padova, Italy.
M LorentzonMary McKillop Health Institute, Australian Catholic University, Melbourne, Australia.
C CooperMRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.
R RizzoliService of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
G AdibSyrian National Osteoporosis Society, Damascus, Syria.
N Al-DaghriChair for Biomarkers of Chronic Diseases, Biochemistry Dept., College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia.
C CampusanoClinica Universidad de los Andes and Faculty of Medicine, Universidad de los Andes, Santiago, Chile.
M ChandranOsteoporosis and Bone Metabolism Unit, Department of Endocrinology, Singapore General Hospital, ACADEMIA, 20, College Road, Singapore, 169856, Singapore.
B Dawson-HughesJean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA.
K JavaidNIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK.
F JiwaChair of the Committee of Patients Societies at the International Osteoporosis Foundation, Osteoporosis Canada, Toronto, Canada.
H JohanssonCentre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, S10 2RX, Sheffield, UK.
J K LeeBeacon International Specialist Centre, Petaling Jaya, Malaysia.
E LiuMary McKillop Health Institute, Australian Catholic University, Melbourne, Australia.
D MessinaIRO Medical Research Center, Buenos Aires and Rheumatology section, Cosme Argerich, Buenos Aires, Argentina.
O MkinsiDepartment of Rheumatology, Ibn Rochd University Hospital, Casablanca, Morocco.
D PintoDepartment of Physical Therapy, Marquette University, Milwaukee, WI, USA.
D Prieto-AlhambraNIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK.
K SaagUniversity of Alabama at Birmingham, Birmingham, AL, USA.
W XiaDepartment of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Shuaifuyuan No. 1, Wangfujing, Dongcheng District, Beijing, 100730, China.
L ZakraouiService de Rhumatologie, University Tunis Manar and Hôpital Mongi-Slim, la Marsa, Tunisia.
J -Y ReginsterChair for Biomarkers of Chronic Diseases, Biochemistry Dept., College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia.

Funding

Department of Health 10/33/04Medical Research Council MC_U147585819Medical Research Council MC_U147585824Medical Research Council MC_U147585827Medical Research Council MR/P020941/1Versus Arthritis 17702
6 · The paper itself

Abstract

Guidance is provided in an international setting on the assessment and specific treatment of postmenopausal women at low, high and very high risk of fragility fractures.

introductionThe International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published guidance for the diagnosis and management of osteoporosis in 2019. This manuscript seeks to apply this in an international setting, taking additional account of further categorisation of increased risk of fracture, which may inform choice of therapeutic approach.

methodsClinical perspective and updated literature search.

resultsThe following areas are reviewed: categorisation of fracture risk and general pharmacological management of osteoporosis.

conclusionsA platform is provided on which specific guidelines can be developed for national use to characterise fracture risk and direct interventions.

Indexed as

AlgorithmsOsteoporosis, PostmenopausalOsteoporotic FracturesAgedBone DensityFemaleHumansMiddle AgedRisk AssessmentRisk FactorsAnabolic agentsFracture risk assessmentFRAXInhibitors of bone resorptionTreatment of osteoporosis

Identifiers

PMID31720707
PMCPMC7018677

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.